Afinion gathers momentum as Axis-Shield moves into profitability for the first time
This article was originally published in Clinica
Executive Summary
Axis-Shield has enlisted long-time partner Abbott Labs as exclusive US distributor of Afinion, its multi-test point-of-care (POC) analyser. The Anglo-Norwegian company received US FDA clearance for its system and HbA1c diabetes test - the first test approved for use on the analyser - in July this year (see Clinica No 1168, p 22).
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: